Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03933943 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3361237 in Participants With Systemic Lupus Erythematosus
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT03933943 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 28 participants.
The verdict
NCT03933943, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The main purpose of this study is to learn more about the safety of LY3361237 and any side effects that might be associated with it when given to participants with systemic lupus erythematosis (SLE). LY3361237 will be administered by injections just under the skin. The study will last up to 26 weeks and may include up to 17 visits to the study center.
Interventions
- DRUG Placebo
- DRUG LY3361237
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2019-05-21 |
| Est. Completion | 2021-02-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03933943
The ClinicalTrials.gov registry entry for NCT03933943 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03933943 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03933943 about?
NCT03933943 is a clinical study titled "A Study of LY3361237 in Participants With Systemic Lupus Erythematosus". The main purpose of this study is to learn more about the safety of LY3361237 and any side effects that might be associated with it when given to participants with systemic lupus erythematosis (SLE). LY3361237 will be administered by injections just under the skin. The study will last up to 26 weeks...
What is the current status of trial NCT03933943?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2019-05-21. Estimated completion is 2021-02-15.
What interventions are being tested in trial NCT03933943?
The interventions under investigation include: Placebo (DRUG), LY3361237 (DRUG).
Who is sponsoring clinical trial NCT03933943?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.